Pars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities

Table 2

Changes in visual acuity and OCT measurements during the study period.

Months	CDVA (LogMAR)		value	CSFT(µm)		value
	Group I (n = 20)	Group II (n = 20)		Group I (n = 20)	Group II (n = 20)
Baseline	0.78 ± 0.29	0.83 ± 0.28	0.618	516 ± 93	527 ± 116	0.759
1^st	0.63 ± 0.27	0.83 ± 0.27	0.027	446 ± 107	382 ± 77	0.036
2^nd	0.59 ± 0.26	0.79 ± 0.24	0.017	404 ± 106	348 ± 83	0.068
3^rd	0.60 ± 0.27	0.79 ± 0.26	0.032	381 ± 112	325 ± 88	0.090
4^th	0.58 ± 0.28	0.78 ± 0.25	0.024	370 ± 105	321 ± 90	0.129
5^th	0.57 ± 0.30	0.78 ± 0.27	0.030	384 ± 106	317 ± 93	0.038
6^th	0.56 ± 0.29	0.74 ± 0.29	0.061	355 ± 105	311 ± 94	0.172
^Fp value	<0.001	0.115		<0.001	<0.001

Group I: ranibizumab; Group II: pars plana vitrectomy; t: Student’s t-test; F: F test (ANOVA); CDVA: corrected distance visual acuity; CSFT: central subfield thickness. Statistically significant at .